BioNTech (United States)

Recent papers from BioNTech (United States)

1. Beyond measurement: a strategic perspective on antibody–drug conjugates bioanalysis from the European Bioanalysis ForumBioanalysis · 2026
2. Cancer-specific T cell receptor discovery using 150,000 clinical genomics samplesScience Translational Medicine · 2026
3. BenchMHC: a reproducible framework for peptide-MHC presentation prediction2026
4. Diversity of ITS Genotypes in Trichophyton mentagrophytes Species Complex Isolates Causing Tinea Corporis and Tinea Capitis: A Multicenter Study in FranceMedical Mycology · 2026
5. Population pharmacokinetics for the CTLA‐4 modulator gotistobart in patients with advanced solid tumorsThe Journal of Clinical Pharmacology · 2026
6. Histological, functional, and behavioral comparison of three Duchenne muscular dystrophy mouse modelsNeuromuscular Disorders · 2026
7. A chimeric, half-life extended lysin with a unique mode of actionFrontiers in Microbiology · 2026
8. An Exploratory Evaluation of the Present Prevalence of Hepatitis D Infection in Selected Populations from Venezuela, Contrasted with Past Studies in the CountryMicroorganisms · 2026
9. Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy AdultsVaccines · 2026
10. 83RO Trastuzumab pamirtecan (T-Pam/DB-1303/BNT323) in patients (pts) with previously treated, HER2-expressing, advanced endometrial cancer (EC): Overall survival (OS) and efficacy in pt subgroups of a phase II dose-expansion cohortESMO Open · 2026
11. Safety and immunogenicity of BNT162b2 in ART-treated PWHOpen Forum Infectious Diseases · 2026
12. Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activityiScience · 2026
13. Real‐World Evidence of Treatment Patterns, Time to Real‐World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United StatesCancer Medicine · 2026
14. One-step cleavage and purification: a bifunctional IdeS-Protein A fusion protein for on-column generation of antibody fragmentsmAbs · 2026
15. Correction: Ishida et al. Wnt/β-Catenin Signaling Regulates Hepatitis B Virus cccDNA Levels. Int. J. Mol. Sci. 2025, 26, 6942International Journal of Molecular Sciences · 2026
16. PET-Guided Modeling of Mucosal Boron Heterogeneity Improves Dose-Toxicity Prediction in BNCTInternational Journal of Radiation Oncology*Biology*Physics · 2026
17. BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.Journal of Clinical Oncology · 2026
18. Fern-EC-01 (BNT323-01): A phase 3 trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in patients with previously treated, HER2-expressing, recurrent endometrial cancer (EC).Journal of Clinical Oncology · 2026
19. BNT324-03: Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC).Journal of Clinical Oncology · 2026
20. A phase I study of HPB-092, a dual FLT3/IRAK4 inhibitor, in relapsed or refractory acute myeloid leukemia.Journal of Clinical Oncology · 2026